{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:49:39Z","timestamp":1793746179541,"version":"4.6.1"},"reference-count":104,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gastrojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1053\/j.gastro.2018.11.037","type":"journal-article","created":{"date-parts":[[2018,11,22]],"date-time":"2018-11-22T18:41:16Z","timestamp":1542912076000},"page":"355-368.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"title":["New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection"],"prefix":"10.1053","volume":"156","author":[{"given":"Carla S.","family":"Coffin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kali","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah A.","family":"Terrault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.gastro.2018.11.037_bib1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib2","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jhep.2018.05.017","article-title":"New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings","volume":"69","author":"Chevaliez","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib3","series-title":"Guidelines on Hepatitis B and C Testing: 2017","year":"2017"},{"key":"10.1053\/j.gastro.2018.11.037_bib4","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1186\/s12879-017-2772-3","article-title":"Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis","volume":"17","author":"Amini","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1053\/j.gastro.2018.11.037_bib5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1423-0410.2009.01272.x","article-title":"Performance evaluation of 70 hepatitis B virus (HBV) surface antigen (HBsAg) assays from around the world by a geographically diverse panel with an array of HBV genotypes and HBsAg subtypes","volume":"98","author":"Scheiblauer","year":"2010","journal-title":"Vox Sang"},{"key":"10.1053\/j.gastro.2018.11.037_bib6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcv.2013.11.010","article-title":"Performance of a new rapid test for the detection of hepatitis B surface antigen in various patient populations","volume":"59","author":"Chevaliez","year":"2014","journal-title":"J\u00a0Clin Virol"},{"key":"10.1053\/j.gastro.2018.11.037_bib7","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jvh.12257","article-title":"A\u00a0simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation","volume":"21","author":"Gish","year":"2014","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2018.11.037_bib8","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1128\/JCM.02980-14","article-title":"Validation of rapid point-of-care (POC) tests for detection of hepatitis B surface antigen in field and laboratory settings in the Gambia, Western Africa","volume":"53","author":"Njai","year":"2015","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1053\/j.gastro.2018.11.037_bib9","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1186\/s12879-017-2777-y","article-title":"Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried blood spot samples (DBS): two systematic reviews and meta-analyses","volume":"17","author":"Lange","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1053\/j.gastro.2018.11.037_bib10","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1186\/s12879-017-2776-z","article-title":"Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples\u2014a systematic review and meta-analysis","volume":"17","author":"Lange","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1053\/j.gastro.2018.11.037_bib11","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jhep.2012.11.016","article-title":"Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France","volume":"58","author":"Bottero","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jcv.2017.09.012","article-title":"Performance of rapid diagnostic tests for the detection of anti-HBs in various patient populations","volume":"96","author":"Poiteau","year":"2017","journal-title":"J\u00a0Clin Virol"},{"key":"10.1053\/j.gastro.2018.11.037_bib13","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1128\/JCM.40.12.4603-4606.2002","article-title":"Evaluation of a new rapid test for the combined detection of hepatitis B virus surface antigen and hepatitis B virus e antigen","volume":"40","author":"Clement","year":"2002","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1053\/j.gastro.2018.11.037_bib14","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.037_bib15","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of\u00a0hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"Sarin","year":"2016","journal-title":"Hepatol Int"},{"key":"10.1053\/j.gastro.2018.11.037_bib17","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1046\/j.1537-2995.2003.00424.x","article-title":"Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection","volume":"43","author":"Biswas","year":"2003","journal-title":"Transfusion"},{"key":"10.1053\/j.gastro.2018.11.037_bib18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3389\/fmed.2018.00029","article-title":"Hepatitis B virus blood screening: need for reappraisal of blood safety measures?","volume":"5","author":"Candotti","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1053\/j.gastro.2018.11.037_bib19","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/jmv.21706","article-title":"Comparison of the technical and clinical performance of the Elecsys HBsAg II assay with the Architect, AxSym, and Advia Centaur HBsAg screening assays","volume":"82","author":"Louisirirotchanakul","year":"2010","journal-title":"J\u00a0Med Virol"},{"key":"10.1053\/j.gastro.2018.11.037_bib20","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/hep.24318","article-title":"Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice","volume":"53","author":"Hongthanakorn","year":"2011","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.037_bib21","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/hep.23571","article-title":"Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers","volume":"51","author":"Thompson","year":"2010","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.037_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1053\/j.gastro.2018.11.037_bib23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jcv.2010.12.008","article-title":"Correlation between the Elecsys HBsAg II assay and the Architect\u00a0assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum","volume":"50","author":"Wursthorn","year":"2011","journal-title":"J\u00a0Clin Virol"},{"key":"10.1053\/j.gastro.2018.11.037_bib24","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1111\/1469-0691.12739","article-title":"Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B","volume":"20","author":"Seto","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1053\/j.gastro.2018.11.037_bib25","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1136\/gutjnl-2017-313811","article-title":"Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers","volume":"67","author":"Pfefferkorn","year":"2018","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.11.037_bib26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib27","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/jvh.12643","article-title":"Determination of hepatitis B phenotype using biochemical and serological markers","volume":"24","author":"Di Bisceglie","year":"2017","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2018.11.037_bib28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.gastro.2010.04.052","article-title":"Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers","volume":"139","author":"Brunetto","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.11.037_bib29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/hep.28552","article-title":"Serum levels of hepatitis B surface antigen and DNA can predict inactive carriers with low risk of disease progression","volume":"64","author":"Liu","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.037_bib30","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.jhep.2012.12.006","article-title":"A\u00a0predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection","volume":"58","author":"Liu","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib31","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/hep.28589","article-title":"Quantitative maternal hepatitis B surface antigen predicts maternally transmitted hepatitis B virus infection","volume":"64","author":"Wen","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.037_bib32","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1053\/j.gastro.2012.02.007","article-title":"High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load","volume":"142","author":"Tseng","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.11.037_bib33","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib34","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.3748\/wjg.v20.i24.7686","article-title":"Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues","volume":"20","author":"Chen","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2018.11.037_bib35","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.24615","article-title":"Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load","volume":"55","author":"Tseng","year":"2012","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.037_bib36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","article-title":"Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B","volume":"140","author":"Heathcote","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.11.037_bib37","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jhep.2014.07.019","article-title":"Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate","volume":"61","author":"Marcellin","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib38","doi-asserted-by":"crossref","first-page":"e43143","DOI":"10.1371\/journal.pone.0043143","article-title":"Hepatitis B surface antigen concentrations in patients with HIV\/HBV co-infection","volume":"7","author":"Jaroszewicz","year":"2012","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2018.11.037_bib39","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jhep.2014.04.029","article-title":"The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment","volume":"61","author":"Chen","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2018.11.037_bib40","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/liv.12735","article-title":"HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients","volume":"35","author":"Martinot-Peignoux","year":"2015","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2018.11.037_bib41","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.037_bib42","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jhep.2011.12.007","article-title":"Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a","volume":"56","author":"Rijckborst","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib43","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1053\/j.gastro.2012.05.039","article-title":"Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir","volume":"143","author":"Hadziyannis","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.11.037_bib44","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/apt.13272","article-title":"Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B","volume":"42","author":"Chang","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2018.11.037_bib45","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/ajg.2016.109","article-title":"Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg","volume":"111","author":"Wang","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1053\/j.gastro.2018.11.037_bib46","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/jvh.12851","article-title":"The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients","volume":"25","author":"Chen","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2018.11.037_bib47","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1093\/infdis\/jix690","article-title":"Distinct relapse rates and risk predictors after discontinuing tenofovir and entecavir therapy","volume":"217","author":"Su","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1053\/j.gastro.2018.11.037_bib48","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2036.2011.04738.x","article-title":"Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy","volume":"34","author":"Liang","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2018.11.037_bib49","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/hep.29497","article-title":"Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg-negative chronic hepatitis B","volume":"68","author":"Papatheodoridis","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.037_bib50","article-title":"Bi-weekly dosing of ARB-1467 LNP siRNA in HBeAg negative, virally suppressed patients with chronic HBV infection leads to deeper declines in HBSAG and potential association with IL28B","volume":"2017","author":"Agarwal","year":"2017","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.037_bib51","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.3748\/wjg.v20.i18.5427","article-title":"Hepatitis B virus genotypes: global distribution and clinical importance","volume":"20","author":"Sunbul","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1053\/j.gastro.2018.11.037_bib52","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2007.08.010","article-title":"Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F","volume":"133","author":"Livingston","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.11.037_bib53","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/apt.12207","article-title":"Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma","volume":"37","author":"Wong","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2018.11.037_bib54","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0016-5085(00)70261-7","article-title":"Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B","volume":"118","author":"Kao","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.11.037_bib55","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1053\/gast.2002.37041","article-title":"Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients","volume":"123","author":"Sanchez-Tapias","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.11.037_bib56","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/hep.20240","article-title":"HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects","volume":"39","author":"Yuen","year":"2004","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.037_bib57","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jhep.2017.07.011","article-title":"How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?","volume":"67","author":"Rajoriya","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib58","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.11.037_bib59","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/gut.2005.089722","article-title":"Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B","volume":"56","author":"Bonino","year":"2007","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.11.037_bib60","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/135965350801300217","article-title":"Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence","volume":"13","author":"Wiegand","year":"2008","journal-title":"Antivir Ther"},{"key":"10.1053\/j.gastro.2018.11.037_bib61","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2009.12.014","article-title":"Is response to antiviral treatment influenced by hepatitis B virus genotype?","volume":"52","author":"Raimondi","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib62","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2011.11.012","article-title":"Quantitative dynamics\u00a0of hepatitis B basal core promoter and precore mutants before and after HBeAg seroconversion","volume":"56","author":"Nie","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib63","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/hep.28222","article-title":"Predictors of hepatitis B e antigen-negative hepatitis in chronic hepatitis B virus-infected patients from childhood to adulthood","volume":"63","author":"Wu","year":"2016","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.037_bib64","doi-asserted-by":"crossref","first-page":"12525","DOI":"10.18632\/oncotarget.7123","article-title":"Naturally occurring basal core promoter A1762T\/G1764A dual mutations increase the risk of HBV-related hepatocellular carcinoma: a meta-analysis","volume":"7","author":"Yang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1053\/j.gastro.2018.11.037_bib65","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djn243","article-title":"Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma","volume":"100","author":"Yang","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1053\/j.gastro.2018.11.037_bib66","doi-asserted-by":"crossref","first-page":"e38394","DOI":"10.1371\/journal.pone.0038394","article-title":"Precore mutation of hepatitis B virus may contribute to hepatocellular carcinoma risk: evidence from an updated meta-analysis","volume":"7","author":"Liao","year":"2012","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2018.11.037_bib67","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1136\/gutjnl-2015-309300","article-title":"Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B","volume":"66","author":"Bayliss","year":"2017","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.11.037_bib68","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/apt.13170","article-title":"Higher lifetime chance of spontaneous surface antigen loss in hepatitis B carriers\u00a0with genotype C infection","volume":"41","author":"Tseng","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2018.11.037_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/v9060156","article-title":"The role of cccDNA in HBV maintenance","volume":"9","author":"Allweiss","year":"2017","journal-title":"Viruses"},{"key":"10.1053\/j.gastro.2018.11.037_bib70","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1038\/emi.2014.64","article-title":"Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance","volume":"3","author":"Yang","year":"2014","journal-title":"Emerg Microbes Infect"},{"issue":"Suppl 1","key":"10.1053\/j.gastro.2018.11.037_bib71","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/liv.13001","article-title":"Clinical relevance of the study of hepatitis B virus covalently closed circular DNA","volume":"36","author":"Kumar","year":"2016","journal-title":"Liver Int"},{"key":"10.1053\/j.gastro.2018.11.037_bib72","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.virusres.2017.06.010","article-title":"The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA","volume":"244","author":"Yang","year":"2018","journal-title":"Virus Res"},{"key":"10.1053\/j.gastro.2018.11.037_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/v9060139","article-title":"Detection of HBV covalently closed circular DNA","volume":"9","author":"Li","year":"2017","journal-title":"Viruses"},{"key":"10.1053\/j.gastro.2018.11.037_bib74","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","article-title":"Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy","volume":"126","author":"Werle-Lapostolle","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.11.037_bib75","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1245\/s10434-013-3046-y","article-title":"Impact of intrahepatic hepatitis B DNA and covalently closed circular DNA on survival after hepatectomy in HBV-associated hepatocellular carcinoma patients","volume":"20","author":"Wang","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1053\/j.gastro.2018.11.037_bib76","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1053\/j.gastro.2018.11.037_bib77","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jhep.2010.12.036","article-title":"Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence","volume":"55","author":"Lenci","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib78","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jmoldx.2018.01.010","article-title":"A\u00a0highly sensitive and robust method for hepatitis B virus covalently closed circular DNA detection in single cells and serum","volume":"20","author":"Huang","year":"2018","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1053\/j.gastro.2018.11.037_bib79","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","author":"Wang","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib80","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1053\/j.gastro.2007.06.057","article-title":"Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients","volume":"133","author":"Volz","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1053\/j.gastro.2018.11.037_bib81","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2016.09.028","article-title":"Serum HBV pgRNA as a clinical marker for cccDNA activity","volume":"66","author":"Giersch","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib82","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.27381","article-title":"Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors","volume":"61","author":"van Bommel","year":"2015","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.037_bib83","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/hep.29872","article-title":"Host and viral factors associated with serum hepatitis\u00a0B virus RNA levels among patients in need for treatment","volume":"68","author":"van Campenhout","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.037_bib84","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/jvh.12908","article-title":"Natural history of serum HBV-RNA in chronic HBV infection","volume":"25","author":"Wang","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2018.11.037_bib85","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/infdis\/jiv397","article-title":"Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa-2a and nucleos(t)ide analogues","volume":"213","author":"Jansen","year":"2016","journal-title":"J\u00a0Infect Dis"},{"key":"10.1053\/j.gastro.2018.11.037_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/hep.30082","article-title":"Hepatitis B virus serum DNA and RNA levels in nucleos(t)ide analog-treated or untreated patients during chronic and acute infection","author":"Butler","year":"2018","journal-title":"Hepatology"},{"key":"10.1053\/j.gastro.2018.11.037_bib87","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1309\/AJCP8QDN7NAUXJFJ","article-title":"Performance evaluation of new automated hepatitis B viral markers in the clinical laboratory: two quantitative hepatitis B surface antigen assays and an HBV core-related antigen assay","volume":"137","author":"Park","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.gastro.2018.11.037_bib88","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/jvh.12889","article-title":"HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues","volume":"25","author":"Wang","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2018.11.037_bib89","doi-asserted-by":"crossref","first-page":"306 e7","DOI":"10.1016\/j.cmi.2017.07.016","article-title":"Predictive\u00a0role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy","volume":"24","author":"Chuaypen","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1053\/j.gastro.2018.11.037_bib90","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/apt.14376","article-title":"Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection","volume":"47","author":"Mak","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.gastro.2018.11.037_bib91","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.4254\/wjh.v8.i34.1511","article-title":"On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B","volume":"8","author":"Gao","year":"2016","journal-title":"World J Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib92","doi-asserted-by":"crossref","first-page":"e61297","DOI":"10.1371\/journal.pone.0061297","article-title":"Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals","volume":"8","author":"Matthews","year":"2013","journal-title":"PLoS One"},{"key":"10.1053\/j.gastro.2018.11.037_bib93","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7754\/Clin.Lab.2017.170916","article-title":"Quantitative hepatitis B e Antigen: a better predictor of hepatitis B virus DNA than quantitative hepatitis B surface antigen","volume":"64","author":"Hudu","year":"2018","journal-title":"Clin Lab"},{"key":"10.1053\/j.gastro.2018.11.037_bib94","doi-asserted-by":"crossref","first-page":"e7766","DOI":"10.1097\/MD.0000000000007766","article-title":"Serum HBeAg and HBV DNA levels are not always proportional and only high levels of HBeAg most likely correlate with high levels of HBV DNA: a community-based study","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1053\/j.gastro.2018.11.037_bib95","series-title":"Collaborative Study to Establish a World Health Organization International Standard for Hepatitis B e Antigen (HBeAg)","year":"2013"},{"key":"10.1053\/j.gastro.2018.11.037_bib96","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1136\/gutjnl-2012-302656","article-title":"Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients","volume":"62","author":"Yuan","year":"2013","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.11.037_bib97","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.cmi.2014.10.002","article-title":"Quantitative hepatitis B\u00a0core antibody levels in the natural history of hepatitis B virus infection","volume":"21","author":"Song","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1053\/j.gastro.2018.11.037_bib98","doi-asserted-by":"crossref","first-page":"E133","DOI":"10.1111\/hepr.12937","article-title":"Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near-normal alanine aminotransferase levels","volume":"48","author":"Li","year":"2018","journal-title":"Hepatol Res"},{"key":"10.1053\/j.gastro.2018.11.037_bib99","article-title":"Association between high levels of hepatitis B Core antibody and seroclearance of hepatitis B e antigen in individuals with chronic hepatitis B virus infection","author":"Liu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib100","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/gutjnl-2014-308546","article-title":"Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues","volume":"65","author":"Fan","year":"2016","journal-title":"Gut"},{"key":"10.1053\/j.gastro.2018.11.037_bib101","article-title":"Serum level of antibodies against hepatitis B core protein is associated with clinical relapse after discontinuation of nucleos(t)ide analogue therapy","author":"Chi","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.gastro.2018.11.037_bib102","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1080\/23744235.2018.1442018","article-title":"Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy","volume":"50","author":"Wang","year":"2018","journal-title":"Infect Dis (Lond)"},{"key":"10.1053\/j.gastro.2018.11.037_bib103","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jvh.12565","article-title":"Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients","volume":"23","author":"Martinot-Peignoux","year":"2016","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1053\/j.gastro.2018.11.037_bib104","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3851\/IMP3136","article-title":"Elevated pre-treatment IL-18 level is associated with HBeAg seroconversion in HIV-HBV coinfection","volume":"22","author":"Li","year":"2017","journal-title":"Antivir Ther"}],"container-title":["Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508518352855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0016508518352855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:44:06Z","timestamp":1762163046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0016508518352855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":104,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0016508518352855"],"URL":"https:\/\/doi.org\/10.1053\/j.gastro.2018.11.037","relation":{},"ISSN":["0016-5085"],"issn-type":[{"value":"0016-5085","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New and Old Biomarkers for Diagnosis and Management of Chronic Hepatitis B Virus Infection","name":"articletitle","label":"Article Title"},{"value":"Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.gastro.2018.11.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the AGA Institute","name":"copyright","label":"Copyright"}]}}